Biomedical subjects

J Boda

Publications and source records attributed to J Boda.

7 recordsLinked to original sources

PubMed2003

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.

OBJECTIVE: To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia. PATIENTS AND METHODS: Fifty-two patients were investigated for the three-month effect of 200 mg per day micronised fenofibrate on the serum enzyme activity and concentration of PON and their relationship with serum lipids, high-density lipoprotein (HDL-C) parameters. RESULTS: Serum paraoxonase activity was lower in CHD patients with type IIb hyperlipoproteinemia. During the three-month study it was observed that following treatment with micronised fenofibrate, serum triglyceride and cholesterol levels decreased, while HDL-C increased significantly (p<0.001). Low-density lipoprotein (p<0.05) and apolipoprotein B-100 (p<0.01) decreased, while HDL constituent apolipoprotein A-I (p<0.05) increased after micronised fenofibrate treatment. The HDL-associated paraoxonase specific activity increased significantly (p<0.05). To assess whether the increased PON activity was due to elevated HDL and apoA-I level, we standardized PON activity for HDL and apoA-I concentrations. The standardized values for HDL (PON/HDL) increased (p<0.05) while the PON/apoA-I ratio did not change significantly. CONCLUSION: Three months of treatment with micronised fenofibrate is thought to normalize lipid profile and improve antioxidant status by increasing serum paraoxonase activity in these patients.

Adult↗

PubMed1997

[Lipoprotein (a) studies in thyroid diseases].

High lipoprotein (a) levels have been established as a risk factor for atherosclerosis. The physiological and pathological function of lipoprotein (a) and the effect of other factors of lipoprotein (a) plasma concentrations are not well known. The role of thyroid hormones concerning Lp(a) plasma concentrations are not fully cleared. The Lp(a) levels are genetically determined, relatively stable, while the thyroid hormones react differently. 30 hyperthyroid and 29 hypothyroid patients were studied. The thyroid status and lipid parameters were investigated. A significant correlation was observed between the cholesterol, triglyceride, LDL-cholesterol, Apolipoprotein B and the thyroid hormone levels. The HDL-cholesterol and Apolipoprotein A correlated inversely with the thyroid hormone levels. Data obtained on the Lp(a) and thyroid hormone was in contrast with those of other studies. Hyperthyroid patients were increased Lp(a) concentrations as compared those of euthyroid subjects. In severe thyreotoxicosis (especially with high levels of antithyroid antibodies) elevated Lp(a) plasma concentrations were found. In hypothyroid patients the high levels of Lp(a) were measured as described in previous studies. Authors concluded that further studies are needed to investigate this phenomenon.

Apolipoproteins A↗

PubMed1997

[In vitro study of endothelium-dependent relaxation and contraction of human atherosclerotic femoral artery].

According to present knowledge, altered arterial reactivity associated with hypertension, atherosclerosis and hypercholesterolemia is related to impaired release of endothelial derived relaxing factor (EDRF). Impaired relaxation followed by enhanced vasoconstriction leads to a well known clinical entities such as unstable angina, acut myocardial infarction. Impairment of EDRF may also account for smooth muscle cell proliferation and migration. Aim of present study was to examine the endothelial dependent response during in vitro conditions in human femoral arteries taken from bypass operation and leg amputation. Examining the contractility, the effect was modulated with nifedipin, EDTA and pertussis toxin, respectively. Endothelium dependent relaxation to acethylcholin and histamine were markedly diminished, while those to calcium ionophore were maintained throughout the study. These results suggest that at least two or more receptor-coupled system may be involved in generation of EDRF. However, direct relaxation of femoral artery to nitrovasodilatators (nitroglycerine) were comparable between control and atherosclerotic artery. Another striking change in atherosclerotic artery was the increased sensitivity to the vasoconstrictions. To eluciadate to exact biochemical mechanism underlying the endothelial dysfunction may help to develop a new vasodilatator drug.

Arteriosclerosis↗

PubMed1997

[Lipid lowering treatment in secondary prevention following myocardial infarct].

1081 patients treated with myocardial infarction between 1990-1995 were investigated retrospectively, 652 (60.3%) of the patients were male and 429 (39.7%) were female. 154 (14.2%) patients had an early, while 927 (85.5%) patients had late myocardial infarction. Of the patients with early myocardial infarction 52.3% were smokers, 45.2% had positive family history for ischaemic heart disease or acute myocardial infarction. The lipid parameters were analysed in detail, because 83.3% of the patients were hyperlipoproteinaemic. The mean cholesterol level was 6.91 +/- 1.2 mmol/l, the HDL-C level was 1.19 +/- 0.38 mmol/l, the triglyceride level was 2.66 +/- 1.8 mmol/l, the LDL-C level was 4.71 +/- 1.2 mmol/l. The serum LDL-C and the HDL-C levels of the patients with early myocardial infarction were compared to the desirable levels suggested for secondary prevention. Only 7.2% of the male patients had a cholesterol level below 5.2 mmol/l, while all female patients cholesterol levels were above 5.2 mmol/l. Of the male patients 53.6%, while 78.6% of females had lower triglyceride levels than 2.3 mmol/l 78,6% of the male patients had higher protective HDL-C level in the optimal range (> 1.1 mmol/l). 12.5 percent of the male patients had an LDL-C level lower than the value targeted by secondary prevention (3.0 mmol/l), while all of the female patients LDL-C levels were higher. The authors emphasize the importance of secondary prevention and a more widespread use of lipid lowering treatment for patients after acute myocardial infarction.

Adult↗

PubMed1997

Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.

Thirty patients were investigated with hyperlipoproteinaemia, 15 patients with non-insulin dependent diabetes mellitus (NIDDM) and 15 with primary hyperlipoproteinaemia. The patients took 250 mg acipimox (5-metyl-pyrazine-carboxylic acid 4-oxide) 3 times per day for 2 months. Serum examinations were performed before and after 1 and 2 months of acipimox administration. After treatment the cholesterol and triglyceride levels decreased in both groups. Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly. The low density lipoprotein (LDL) level did not change significantly in either groups of patients. The apolipoprotein A 1 (apo A 1) levels increased significantly during the second month of acipimox administration. Uric acid levels decreased in both groups, but significant change could be detected mainly in the NIDDM group. Serum glucose level did not change in the non-diabetic patients, while it decreased significantly in the NIDDM group.

Apolipoprotein A-I↗

PubMed1993

[Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].

The authors give summary on the pathogenesis of hyperlipoproteinaemia in patients with diabetes mellitus. They investigated the effects of acid nicotinic derivate acipimox on lipid metabolism in these patients. They treated with acipimox 15 patients who suffered from non-insulin-dependent diabetes mellitus, as well as II/B, IV type hyperlipoproteinaemia by Fredrickson. They investigated the effect of acipimox on the lipoprotein content and quality in the sera and uric acid and carbohydrate metabolism. The authors found decreased cholesterol, triglyceride, apolipoprotein-B, glycosilated haemoglobin, glucose and uric acid levels in the sera and they found that the atherogenic index decreased too. During the treatment they could not recognise a change in the low-density lipoprotein level of the sera while the high density lipoprotein and apo-A1 level increased.

Adult↗

PubMed1989

Examination of Cavinton effect in elderly diabetic patients.

The effect of Cavinton tablet has been examined in elderly diabetic patients. According to the observations the intellectual performance of the treated patients improved significantly, and their neurological symptoms were moderated as well. The drug did not influence carbohydrate or lipid metabolisms nor did it affect the systemic blood pressure. The results obtained prove that the drug may successfully be used for the treatment of nervous symptoms of elderly diabetic patients. The assure an effective therapy the drug administration has to be started as early as possible--before the development of nervous symptoms. The dosage of the product has to be adjusted individually. Obviously, the currently accepted other drug therapies of manifesting nervous symptoms have to be used as well and the other diseases accompanying advanced age need also be treated.

Aged↗